The hepatic mRNA expression of HO-1, NQO1, and Nrf2 in scutellarin treatment groups are significantly up-regulated, indicating that the antioxidative effect of scutellarin on NAFLD is dependent on the activation of Nrf2/ARE signaling pathway. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.